Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

935
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
935
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

919
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
919
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

798
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
798
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

901
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
901

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

2026 ACC/AHA/HRS advanced training statement on clinical cardiac electrophysiology (Revision of the 2015 ACC/AHA/HRS advanced training statement on clinical cardiac electrophysiology): A report of the ACC Competency Management Committee.

Heart rhythm·2026
Same author

2026 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (Revision of the 2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology): A Report of the ACC Competency Management Committee.

Journal of the American College of Cardiology·2026
Same author

2026 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (Revision of the 2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology): A Report of the ACC Competency Management Committee.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Tenecteplase Improves Door-to-Needle Time in Real-World Acute Stroke Treatment.

Stroke (Hoboken, N.J.)·2026
Same author

Correction: Pregnancy outcomes in C3 glomerulopathy: a retrospective review.

BMC nephrology·2025
Same author

Pregnancy outcomes in C3 glomerulopathy: a retrospective review.

BMC nephrology·2025

相关实验视频

Updated: Jun 15, 2025

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

2.7K

由弗莱卡尼尼德诱导的先进心房间间隔阻塞.

Jillian Hall1, Daniel Edmundowicz1, Edmond Cronin1

  • 1Section of Cardiology, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States of America.

Journal of electrocardiology
|August 28, 2024
PubMed
概括

弗莱卡尼德的毒性会导致先进的心房间隔膜阻塞,严重的心脏导电异常. 这一案例凸显了在弗莱卡尼尼德治疗期间监测心脏功能的必要性.

科学领域:

  • 心脏病学 心脏病学
  • 电子生理学 电子生理学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 心室间阻塞是心房之间的电导延迟.
  • 弗莱卡因是一种抗心律失常药物,具有潜在的前心律失常效应.
  • 药物毒性可以表现为新的导电异常.

研究的目的:

  • 报告一个罕见的先进心房间间隔阻塞病例.
  • 要将这种导电异常归因于弗莱卡因的毒性.
  • 讨论弗莱卡尼德诱导的心脏间阻塞的临床影响.

主要方法:

  • 案例报告的呈现方式.
  • 审查患者的临床病史和药物治疗.
  • 电心电图分析以确定导电异常.

主要成果:

  • 患者在施用弗莱卡因尼德后出现了先进的心房间隔膜阻塞.
  • 弗莱凯尼德毒性被确定为引起因素.
  • 间阻塞代表了显著的导电延迟.

结论:

  • 弗莱卡因胺的毒性可以诱导先进的心房间隔膜阻塞.
关键词:
先进的心房间间隔阻塞.巴克曼的捆绑包.弗莱卡尼尼德是一种类物质.弗莱卡尼德的毒性 毒性P波是P波,而P波是P波.

更多相关视频

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.6K

相关实验视频

Last Updated: Jun 15, 2025

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

2.7K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.6K
  • 这种导电异常具有显著的临床影响.
  • 在接受 flecainide 治疗的患者中,必须进行仔细的监测.